<DOC>
	<DOCNO>NCT01288963</DOCNO>
	<brief_summary>The purpose study determine participant melanoma good response IL-2 identify marker may predict response IL-2 collecting participant information ( example ; cancer diagnosis history , prior treatment cancer , etc . ) blood tumor sample prior treatment tumor measurement treatment .</brief_summary>
	<brief_title>IL-2 `` SELECT '' Tissue Collection Protocol Patients With Advanced Melanoma</brief_title>
	<detailed_description>Original tumor slide collect identify tumor marker may predict response treatment . Blood sample obtain prior treatment IL-2 .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Malignant melanoma metastatic unresectable Eligible receive highdose IL2 Tissue block available adequate tumor perform RNA extraction DASL analysis Prior immunotherapy unresectable metastatic disease Untreated brain metastasis , leptomeningeal disease , seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>melanoma</keyword>
	<keyword>IL-2</keyword>
	<keyword>Aldesleukin</keyword>
</DOC>